See the DrugPatentWatch profile for lipitor

The factors that affect Lipitor (atorvastatin) dosage review frequency are primarily related to the drug's patent status, regulatory approvals, and safety updates.

1. Patent Expiration: The frequency of dosage reviews for Lipitor can be influenced by the expiration of its patent protection. Once a drug's patent expires, generic versions become available, increasing competition and potentially leading to more frequent reviews of the drug's dosage [1].

2. Regulatory Approvals: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), review and approve drug dosages based on clinical trial data and other evidence. Any updates or changes to the approved dosage regimens can lead to more frequent reviews [1].

3. Safety Updates and Post-Marketing Surveillance: As new safety information becomes available through post-marketing surveillance and ongoing research, regulatory agencies may require updates to drug labels, including changes to dosage recommendations. These updates can result in more frequent reviews of the drug's dosage [1].

4. Treatment Guidelines: Professional medical organizations periodically update treatment guidelines, which can affect the recommended dosages for specific drugs. These updates may prompt more frequent reviews of the drug's dosage [1].

5. Formulation Changes: Changes to a drug's formulation, such as the development of new dosage forms (e.g., extended-release tablets) or combinations with other drugs, can lead to revised dosage recommendations and more frequent reviews [1].

Sources:
[1] DrugPatentWatch.com. (n.d.). Atorvastatin (Lipitor) Drug Patent Expiration, Generic Launch Dates. Retrieved from https://www.drugpatentwatch.com/drugs/atorvastatin/